Researchers sought to identify predictors of movement and neurocognitive treatment-emergent adverse events in patients undergoing CAR-T therapy with ciltacabtagene autoleucel.
Researchers sought to determine whether tisagenlecleucel would be safe and effective in patients with primary central nervous system lymphoma.
Long-term data from 62 of 69 patients in a single-phase 2 trial to determine the efficacy of a combination of anti-BCMA and anti-CD19 CAR-T therapies are presented.
Researchers sought to determine whether liso-cel would have acceptable toxicity and effectiveness in patients with SLL or CLL.
Researchers sought to determine whether tisagenlecleucel is safe and effective in patients younger than 3 years old with relapsed/refractory ALL.
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.
Researchers sought to determine the reasons for a disparity in patients who receive CAR-T therapy.
Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.
A phase 1 trial is currently evaluating the safety and tolerability of ADI-001 in 76 participants with B cell malignancies.
Researchers are working towards developing CAR-T therapy to provide longer and more durable responses for patients with CLL.
